Pmlive

Pmlive PMLiVE.com is the online home to PME, Communiqué and The Directory. Sign-up for online copies: http://www.pmlive.com/register
(1)

Sign-up for online copies: http://www.pmlive.com/register

You can also find us here:
Twitter: https://twitter.com/pmlivecom
LinkedIn: https://www.linkedin.com/company/pmgroup-worldwide-ltd
Google Plus: https://plus.google.com/+pmlivecom
YouTube: https://www.youtube.com/user/PMLiVETV

The PMLiVE website and its associated monthly print magazine Pharmaceutical Market Europe (PME) and twice-yearly p

rint titles Communiqué and The Directory are published by PMGroup. The website offers the latest pharma news, analysis, jobs and events, including the annual Pharmaceutical Market Excellence Awards (PMEAs), Communiqué Awards and the Quality in Care (QiC) Programme.

Gilead appoints Keeley Wettan as Executive VP, General Counsel, Legal & Compliance
10/01/2026

Gilead appoints Keeley Wettan as Executive VP, General Counsel, Legal & Compliance

Wettan has served at Gilead for over 14 years

BMS announces affordable drug price agreement with US government
09/01/2026

BMS announces affordable drug price agreement with US government

The company will provide Eliquis, its oral blood thinner, free of charge to Medicaid

The Heart and Mouth Connection Every Woman Needs to Know
09/01/2026

The Heart and Mouth Connection Every Woman Needs to Know

For decades, modern medicine has treated the mouth and the body as separate entities. But for Dr. Nieca Goldberg, a renowned cardiologist, and Dr. Maria Ryan, Chief Clinical Officer at Colgate-Palmolive, this "siloed" approach is a barrier to true wellness—especially for women.

AstraZeneca’s Saphnelo demonstrates positive results in systemic lupus erythematosus
09/01/2026

AstraZeneca’s Saphnelo demonstrates positive results in systemic lupus erythematosus

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US

Lilly announces acquisition of Ventyx Biosciences for around $1.2bn
08/01/2026

Lilly announces acquisition of Ventyx Biosciences for around $1.2bn

Multiple Ventyx drugs are currently in phase 2 development for inflammatory disease

Excellence in Healthcare Partnerships Awards and Networking Evening
07/01/2026

Excellence in Healthcare Partnerships Awards and Networking Evening

The event will include a Keynote Panel discussion with noted speakers from the NHS, the King’s Fund, the ABPI and the ABHI among others

Amgen agrees to lower prescription drug costs in deal with US government
07/01/2026

Amgen agrees to lower prescription drug costs in deal with US government

The company has invested $40bn in US R&D and manufacturing in the past seven years

GSK’s Nucala approved by MHRA for uncontrolled COPD
07/01/2026

GSK’s Nucala approved by MHRA for uncontrolled COPD

Symptoms of COPD include breathlessness, persistent cough and frequent chest infections

MM+M Podcast explores AI-powered audience intelligence with Inizio Evoke
07/01/2026

MM+M Podcast explores AI-powered audience intelligence with Inizio Evoke

The MM+M Podcast features a conversation with Jamie Avallone, Chief Data Officer at Inizio Evoke, and Iris Lin, Product Science Lead at Inizio Evoke, who share their perspectives on what AI-powered audience intelligence means for life sciences organizations heading into 2026.

Inizio Ignite Sparks a New Era of Connected Advisory Solutions
07/01/2026

Inizio Ignite Sparks a New Era of Connected Advisory Solutions

Inizio, a leading global commercialization partner for pharma and life sciences, today unveiled Inizio Ignite, a reimagined, fully integrated advisory partner designed to accelerate pharma performance through strategy, insights, and innovation.

Uncovering Inequities in Alzheimer’s Disease Screening and Care
07/01/2026

Uncovering Inequities in Alzheimer’s Disease Screening and Care

On December 5, MAPS hosted an educational webinar exploring recent research in Alzheimer’s disease (AD) screening, testing, and treatment. Experts from Komodo

Novartis agrees to lower drug prices in deal with US government
07/01/2026

Novartis agrees to lower drug prices in deal with US government

In 2025, the pharma company announced a $23bn US investment commitment

Address

Little Bookham
KT233JG

Opening Hours

Monday 9:30am - 5:30pm
Tuesday 9:30am - 5:30pm
Wednesday 9:30am - 5:30pm
Thursday 9:30am - 5:30pm
Friday 9:30am - 5:30pm

Website

Alerts

Be the first to know and let us send you an email when Pmlive posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category